Jul 25, 2019
Merrimack Declares $20 Million Special Dividend
May 30, 2019
Merrimack Pharmaceuticals Announces Completion of Strategic Review, Preservation of Ipsen Milestones and Special Cash Dividend
May 10, 2019
Merrimack Reports First Quarter 2019 Financial Results
Apr 09, 2019
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Merrimack Pharmaceuticals, Inc. - MACK
Apr 04, 2019
Merrimack Discontinues Development of MM-310
Mar 06, 2019
Merrimack Reports Fourth Quarter and Full Year 2018 Financial Results
Oct 19, 2018
Merrimack Discontinues Phase 2 SHERLOC Study of MM-121 in Patients with Non-Small Cell Lung Cancer Due to Futility
Sep 20, 2018
Merrimack Receives $5 Million Milestone Payment from Shire
Sep 06, 2018
Merrimack Completes Enrollment in Randomized Phase 2 SHERLOC Study of MM-121 (seribantumab) in Non-Small Cell Lung Cancer (NSCLC)
Aug 07, 2018
Merrimack Reports Second Quarter 2018 Financial Results
Jul 31, 2018
Merrimack Announces Timing of Second Quarter 2018 Investor Conference Call
Jun 25, 2018
Merrimack Announces Top-Line Results from Randomized Phase 2 Trial of MM-141 in Front-Line Metastatic Pancreatic Cancer
May 29, 2018
Merrimack to Present at the 2018 American Society of Clinical Oncology Annual Meeting
May 01, 2018
Merrimack Announces Timing of First Quarter 2018 Investor Conference Call
Apr 09, 2018
Merrimack to Present Preclinical Data at the 2018 American Association for Cancer Research Annual Meeting
Mar 12, 2018
Merrimack Provides Business Update and Reports 2017 Financial Results
Mar 05, 2018
Merrimack Announces Timing of Full Year 2017 Investor Conference Call and Presentation at the Cowen Health Care Conference
Feb 20, 2018
Merrimack Announces Formation of New Scientific Advisory Board with Extensive Expertise in Precision Oncology
Feb 15, 2018
Merrimack to Present at the 2018 RBC Capital Markets Global Healthcare Conference
Jan 04, 2018
Merrimack to Present at the 36th Annual J.P. Morgan Healthcare Conference